• 1. Evidence for the intrinsic nature of band-gap states electrochemically observed on atomically flat TiO2(110) surfaces?
  Shintaro Takata,Yoshihiro Miura Phys. Chem. Chem. Phys., 2014,16, 24784-24789
• 2. Essential effect of the electrolyte on the mechanical and chemical degradation of LiNi0.8Co0.15Al0.05O2 cathodes upon long-term cycling??
  Xiaoming Liu,Zachary D. Hood,Wangda Li,Donovan N. Leonard,Arumugam Manthiram,Miaofang Chi J. Mater. Chem. A, 2021,9, 2111-2119
• 3. Fate of nitrogen-15 in the subsequent growing season of greenhouse tomato plants (Lycopersicon esculentum Mill) as influenced by alternate partial root-zone irrigation
  Maomao Hou,Fenglin Zhong,Qiu Jin,Enjiang Liu,Jie Feng,Tengyun Wang,Yue Gao RSC Adv., 2017,7, 34392-34400
• 4. Excimer and exciplex formation in a pair of bright phosphorescent isomers constructed from Cu3(pyrazolate)3 and Cu3I3 coordination luminophores?
  Shun-Ze Zhan,Mian Li,Xiao-Ping Zhou,Dan Li,Seik Weng Ng RSC Adv., 2011,1, 1457-1459
• 5. Enabling chloride salts for thermal energy storage: implications of salt purity?
  J. Matthew Kurley,Phillip W. Halstenberg,Abbey McAlister,Stephen Raiman,Richard T. Mayes RSC Adv., 2019,9, 25602-25608

• Solvents and Organic Chemicals Organic Compounds Organic 1,3-dipolar compounds Allyl-type 1,3-dipolar organic compounds C-nitro compounds
• Solvents and Organic Chemicals Organic Compounds Organic 1,3-dipolar compounds Allyl-type 1,3-dipolar organic compounds Organic nitro compounds C-nitro compounds

Ethyl 3-nitroisoxazole-5-carboxylate (CAS No. 1224593-92-3): An Overview of Its Structure, Synthesis, and Applications in Pharmaceutical Research

Ethyl 3-nitroisoxazole-5-carboxylate (CAS No. 1224593-92-3) is a versatile organic compound that has garnered significant attention in the fields of medicinal chemistry and pharmaceutical research. This compound, characterized by its unique isoxazole ring and nitro functional group, exhibits a range of properties that make it a valuable intermediate in the synthesis of various bioactive molecules.

The structure of ethyl 3-nitroisoxazole-5-carboxylate is composed of an isoxazole ring, which is a five-membered heterocyclic compound containing one oxygen and one nitrogen atom. The presence of the nitro group at the 3-position and the carboxylate ester at the 5-position imparts specific chemical reactivity and biological activity to the molecule. The ethyl group attached to the carboxylate ester further influences its solubility and reactivity profiles.

In terms of synthesis, ethyl 3-nitroisoxazole-5-carboxylate can be prepared through several well-established methods. One common approach involves the reaction of ethyl acetoacetate with hydroxylamine hydrochloride to form an intermediate, which is then cyclized in the presence of an acid catalyst to yield the desired isoxazole derivative. Subsequent nitration of the isoxazole ring using a mixture of nitric and sulfuric acids introduces the nitro group at the 3-position. This synthetic route has been optimized for high yields and purity, making it suitable for large-scale production in industrial settings.

Recent studies have highlighted the potential applications of ethyl 3-nitroisoxazole-5-carboxylate in pharmaceutical research. For instance, its ability to act as a precursor in the synthesis of antibacterial agents has been explored. The nitro group can be reduced to an amino group, leading to compounds with enhanced antibacterial activity against both Gram-positive and Gram-negative bacteria. Additionally, derivatives of this compound have shown promise as inhibitors of specific enzymes involved in various disease pathways, such as kinases and proteases.

Another area of interest is the use of ethyl 3-nitroisoxazole-5-carboxylate in the development of anti-inflammatory drugs. The isoxazole ring structure is known to exhibit anti-inflammatory properties, and modifications to this core structure can enhance these effects. Research has shown that compounds derived from this scaffold can effectively inhibit pro-inflammatory cytokines and enzymes, making them potential candidates for treating inflammatory diseases such as arthritis and asthma.

The pharmacological properties of ethyl 3-nitroisoxazole-5-carboxylate have also been investigated in preclinical studies. These studies have demonstrated that derivatives of this compound can cross biological membranes efficiently, suggesting good bioavailability when administered orally or parenterally. Furthermore, preliminary toxicity assessments have indicated that these compounds are generally well-tolerated at therapeutic doses, with minimal side effects observed.

In conclusion, ethyl 3-nitroisoxazole-5-carboxylate (CAS No. 1224593-92-3) is a promising compound with a wide range of applications in pharmaceutical research. Its unique chemical structure and versatile reactivity make it an attractive candidate for the development of new drugs targeting various diseases. Ongoing research continues to uncover new possibilities for this compound, further solidifying its importance in the field of medicinal chemistry.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)